trivalent influenza vaccine
- Generic Name
- trivalent influenza vaccine
Effectiveness of Trivalent Influenza Vaccine (TIV) in Type 2 Diabetes Mellitus (T2DM) Patients With and Without Complications of Chronic Kidney Disease (CKD)
- Conditions
- InfluenzaChronic Kidney DiseasesVaccine ReactionDiabetes Mellitus
- Interventions
- First Posted Date
- 2024-02-09
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Universitas Padjadjaran
- Target Recruit Count
- 76
- Registration Number
- NCT06252051
- Locations
- 🇮🇩
AMC Hospital, Bandung, West Java, Indonesia
Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders
- Conditions
- Plasma Cell Neoplasm
- Interventions
- Biological: Pneumococcal 13-valent Conjugate Vaccine
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Emory University
- Target Recruit Count
- 165
- Registration Number
- NCT04080531
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Emory University Hospital Midtown, Atlanta, Georgia, United States
High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients
- Conditions
- Hematopoietic Cell Transplantation
- Interventions
- Other: Laboratory Biomarker AnalysisBiological: Quadrivalent Inactivated Influenza Vaccine
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 124
- Registration Number
- NCT03179761
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Fred Hutchinson Cancer Center, Seattle, Washington, United States
🇺🇸University of Alabama, Birmingham, Alabama, United States
High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant
- Conditions
- Hematopoietic Cell Transplantation RecipientMalignant NeoplasmInfluenza
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 170
- Registration Number
- NCT02860039
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
🇺🇸UCSF Children's Hospital, San Francisco, California, United States
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- Biological: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine AdsorbedOther: Laboratory Biomarker AnalysisOther: Pharmacological StudyBiological: Pneumococcal 13-valent Conjugate VaccineOther: Quality-of-Life Assessment
- First Posted Date
- 2015-08-10
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Jennifer Woyach
- Target Recruit Count
- 42
- Registration Number
- NCT02518555
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.